JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD)

JPMorgan Chase & Co. decreased its position in MediWound Ltd. (NASDAQ:MDWD) by 95.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,401 shares of the biopharmaceutical company’s stock after selling 75,360 shares during the period. JPMorgan Chase & Co.’s holdings in MediWound were worth $61,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. MetLife Investment Management LLC bought a new position in MediWound during the 3rd quarter valued at about $89,000. Barclays PLC lifted its stake in MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new position in MediWound during the 3rd quarter valued at about $212,000. State Street Corp lifted its stake in MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 45,529 shares during the period. Finally, ARK Investment Management LLC bought a new position in MediWound during the 3rd quarter valued at about $1,806,000. Institutional investors own 46.83% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of MediWound in a research note on Friday, January 10th.

MediWound Stock Down 2.2 %

NASDAQ MDWD opened at $19.15 on Tuesday. MediWound Ltd. has a 52 week low of $11.04 and a 52 week high of $24.00. The firm has a market capitalization of $206.63 million, a P/E ratio of -6.60 and a beta of 0.81. The company has a 50-day moving average price of $17.87 and a 200-day moving average price of $17.75.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the previous year, the business posted ($0.24) EPS. As a group, equities research analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.